share_log

EF Hutton Maintains Buy on Annovis Bio, Maintains $21 Price Target

Benzinga ·  Aug 16 04:21  · Ratings

EF Hutton analyst Jason Kolbert maintains Annovis Bio (NYSE:ANVS) with a Buy and maintains $21 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment